Natera executive chairman sells $7.39 million in stock

Matthew Rabinowitz, the Executive Chairman of Natera, Inc. (NASDAQ:NTRA), recently reported the sale of company shares totaling approximately $7.39 million. The transactions were disclosed in a recent SEC filing. The sale comes as the company, now valued at over $20 billion, has delivered an impressive 65.57% return over the past year. According to InvestingPro analysis, Natera maintains a GOOD overall financial health score.

On March 14, Rabinowitz executed multiple sales of Natera common stock, with prices ranging from $145.3693 to $149.00 per share. The total number of shares sold amounted to 50,000, reducing his direct ownership to 2,365,415 shares. The stock has shown significant momentum, currently trading near its 52-week high of $183, reflecting the company’s strong revenue growth of 56.75% over the last twelve months.

This activity follows a recent acquisition of 2,893 restricted stock units (RSUs) on March 12, which were fully vested upon issuance. However, these RSU transactions did not involve any monetary exchange.

Rabinowitz’s sales are part of routine stock transactions by executives, with the latest move reflecting a strategic approach to managing his holdings in the medical laboratories company.

In other recent news, Natera Inc . reported its fourth-quarter 2024 earnings, which exceeded Wall Street’s expectations with a revenue of $476 million, significantly surpassing the forecasted $409.89 million. The company also reported a narrower-than-anticipated loss per share of -$0.41, compared to the expected -$0.49. Natera’s gross margins improved to 63%, up from 51% the previous year, and they generated $46 million in cash flow during the quarter. In addition to these financial results, Natera has launched the HEROES clinical trial in France to explore treatment de-escalation in metastatic HER2+ breast cancer patients, funded by the French Ministry of Health.

Analysts have responded positively to Natera’s performance and future prospects. TD Cowen maintained a Buy rating on Natera, citing the company’s 2025 guidance, which projects sales surpassing consensus estimates by approximately 5%. Canaccord Genuity also raised its price target for Natera to $195 from $180, following the company’s strong fourth-quarter results. Both firms highlighted the potential for increased sales, higher gross margins, and strategic operational expenditures as key growth levers for the company.

Furthermore, Natera received Medicare coverage for its Signatera test for serial recurrence monitoring in non-small cell lung cancer, expanding its reach in the oncology market. The company’s strategic focus on reimbursement strategies and payer coverage aims to enhance revenue per test, adding to the optimism surrounding its future growth trajectory.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.